Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) EVP Tao Fu sold 5,812 shares of the stock in a transaction that occurred on Tuesday, July 18th. The shares were sold at an average price of $65.00, for a total transaction of $377,780.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Tao Fu also recently made the following trade(s):

  • On Monday, June 26th, Tao Fu sold 7,000 shares of Portola Pharmaceuticals stock. The shares were sold at an average price of $57.14, for a total transaction of $399,980.00.

Shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) traded up 0.48% on Thursday, reaching $65.29. 864,841 shares of the company’s stock were exchanged. The firm’s market capitalization is $3.72 billion. Portola Pharmaceuticals, Inc. has a one year low of $15.68 and a one year high of $67.10. The firm has a 50 day moving average of $48.58 and a 200 day moving average of $38.17.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.46. The business had revenue of $5.12 million for the quarter, compared to analysts’ expectations of $4.21 million. Portola Pharmaceuticals had a negative net margin of 759.21% and a negative return on equity of 106.68%. The company’s quarterly revenue was down 37.9% on a year-over-year basis. During the same period in the previous year, the company posted ($1.15) EPS. On average, equities research analysts predict that Portola Pharmaceuticals, Inc. will post ($4.30) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of US and international trademark and copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/07/20/portola-pharmaceuticals-inc-nasdaqptla-evp-tao-fu-sells-5812-shares.html.

A number of research firms recently commented on PTLA. Credit Suisse Group reissued a “neutral” rating and set a $58.00 target price (up previously from $39.00) on shares of Portola Pharmaceuticals in a research report on Monday, June 26th. Citigroup Inc. set a $51.00 target price on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, April 19th. ValuEngine raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of Portola Pharmaceuticals in a research report on Wednesday, March 22nd. Finally, Morgan Stanley increased their target price on shares of Portola Pharmaceuticals from $50.00 to $70.00 and gave the company an “overweight” rating in a research report on Monday, June 26th. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $60.52.

Several institutional investors have recently made changes to their positions in PTLA. BlackRock Inc. boosted its position in shares of Portola Pharmaceuticals by 68,964.1% in the first quarter. BlackRock Inc. now owns 4,034,725 shares of the biopharmaceutical company’s stock valued at $158,121,000 after buying an additional 4,028,883 shares in the last quarter. Norges Bank purchased a new position in shares of Portola Pharmaceuticals during the fourth quarter valued at about $10,046,000. Bogle Investment Management L P DE purchased a new position in shares of Portola Pharmaceuticals during the first quarter valued at about $12,945,000. FMR LLC boosted its position in shares of Portola Pharmaceuticals by 5.6% in the first quarter. FMR LLC now owns 3,902,000 shares of the biopharmaceutical company’s stock valued at $152,919,000 after buying an additional 205,751 shares in the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Portola Pharmaceuticals by 4.4% in the first quarter. Vanguard Group Inc. now owns 4,614,814 shares of the biopharmaceutical company’s stock valued at $180,855,000 after buying an additional 192,420 shares in the last quarter. 85.23% of the stock is currently owned by institutional investors and hedge funds.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Insider Buying and Selling by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.